Boston Scientific's (BSX) Farapulse and Watchman products are expected to drive upside following the discontinuation of global sales of the Acurate transcatheter aortic valve replacements, Needham said in a note Wednesday.
The company announced earlier Wednesday it will discontinue sales of Acurate neo2 and Acurate Prime as well as halt efforts to secure US Food and Drug Administration and other market approvals after recent discussions with regulators led to increased clinical and regulatory requirements for Acurate products.
Needham said Boston Scientific expects to offset the impact of Acurate's shelving with other growth drivers such as Farapulse and Watchman as the company reiterated its outlook for Q2 and 2025.
"We view any weakness in BSX shares today as a buying opportunity given our expectation that Farapulse and Watchman continue to drive upside to consensus estimates," Needham said. "We expect the Champion trial results to be a major catalyst in H1 2026."
Needham has a buy rating on Boston Scientific, with a $115 price target.
Price: 104.73, Change: -1.45, Percent Change: -1.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.